Abstract
β-blockade has a therapeutic role across the continuum of patients with heart failure (HF), with a demonstrated mortality benefit in stage II and III HF. Concerns regarding initiation and uptitration linger as patients with resting bradycardia, pulmonary, or vascular disease are often unnecessarily excluded from receiving therapy. We will review the risk data on β-blockade and offer therapeutic strategies to help overcome residual barriers to the initiation and uptitration of this important therapy in patients with HF.
Original language | English (US) |
---|---|
Pages (from-to) | 110-116 |
Number of pages | 7 |
Journal | Current Heart Failure Reports |
Volume | 4 |
Issue number | 2 |
DOIs | |
State | Published - Jun 2007 |
Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
- Emergency Medicine